Brief: Hightide Therapeutics Updates On Phase 3 Trials Of Berberine Ursodeoxycholate
15/04/2025 02:34
April 15 (Reuters) - HighTide Therapeutics Inc 2511.HK: TWO PHASE 3 TRIALS OF BERBERINE URSODEOXYCHOLATE MET THEIR PRIMARY ENDPOINTS AND GATED SECONDARY ENDPOINTS Further company coverage: 2511.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HighTide Therapeutics
See all newsBrief: Hightide Therapeutics To Issue Up To 99 Million New Shares At Hk$2.28 Per Share
Brief: Hightide Therapeutics Says Co And Individual Terminate Loan Agreement With Immediate Effect
Brief: Hightide Therapeutics Enters Loan Agreement Up To HK$15 Million
Brief: HighTide Therapeutics Says NMPA China Accepts New Drug Application For HTD1801
Brief: Hightide Therapeutics Posts HY Loss Attributable Of RMB120.3 Mln